Twist Bioscience Corp. co-founder and CEO Emily Leproust explains what her company does as helping scientists move from reading DNA to writing it. Now the South San Francisco company is doing some simple business arithmetic.
With a potential $188 million antibody discovery and license agreement with Bayer, the number of deals in Twist's partnership column are adding up, and Leproust said her company is ready for more.
The 960-employee company has put its own biopharma ambitions on hold. Instead,…
